Welcome to our dedicated page for Trinity Biotech Plc SEC filings (Ticker: TRIB), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
The Trinity Biotech plc (TRIB) SEC filings page on Stock Titan provides access to the company’s U.S. regulatory disclosures, including Form 20-F annual reports and Form 6-K current reports. As a foreign private issuer listed on the Nasdaq Stock Market, Trinity Biotech uses these filings to furnish information on its human diagnostics and diabetes management business, financing arrangements and governance matters.
Form 6-K reports for TRIB frequently include press releases as exhibits, covering topics such as regulatory approvals for offshored and outsourced manufacturing of its TrinScreen HIV and Uni-Gold HIV rapid tests, expansion of its high-capacity HbA1c column system for the Premier Hb9210 analyzer, collaboration on epigenetic analysis for the EpiCapture prostate cancer test, and regulatory clearance for the PreClara Ratio preeclampsia testing service. Other 6-K filings reference amendments to credit agreements with Perceptive Credit Holdings entities, warrant issuances, and results of annual general meetings, including resolutions on auditor appointment and share capital authorities.
Users interested in Trinity Biotech’s capital structure and risk profile can review filings that discuss its term-loan facility, amendments and restatements of its credit agreement, and arrangements that allow potential conversion of portions of debt and certain obligations into equity. Filings also document interactions with Nasdaq regarding listing requirements, such as notices of non-compliance with minimum bid price and market value of publicly held shares thresholds, and subsequent confirmation that the company has regained compliance.
Stock Titan enhances access to these documents with tools that surface key elements of each filing, helping readers quickly identify material related to product approvals, financing terms, shareholder votes and other regulatory disclosures. This allows investors, analysts and other stakeholders to examine the official record of Trinity Biotech’s activities as reported to the U.S. Securities and Exchange Commission.
Trinity Biotech plc filed a prospectus supplement covering the resale by selling shareholders of up to 1,117,818,000 Ordinary Shares, represented by up to 55,890,900 ADSs. The supplement incorporates a recent Form 6-K reporting that Nasdaq notified the company its ADSs no longer meet the minimum bid price requirement of US $1.00 per share after trading below that level for 30 consecutive business days. Trinity Biotech has 180 calendar days, until August 10, 2026, to regain compliance while its ADSs, which last traded at $0.77 on February 13, 2026, remain listed on the Nasdaq Global Select Market.
Trinity Biotech plc received a notice from Nasdaq that its American Depositary Shares are not in compliance with the Nasdaq Global Select Market’s minimum bid price requirement of $1.00 per share, after trading below this level for 30 consecutive business days.
The company has 180 calendar days, until August 10, 2026, to regain compliance by having its closing bid price at or above $1.00 for at least ten consecutive business days. The notice has no immediate effect on the listing, and the ADSs continue to trade on the Nasdaq Global Select Market under the symbol TRIB.
If compliance is not regained within this period, the company may qualify for additional time on The Nasdaq Capital Market if it meets the minimum value of publicly held shares requirement of $15,000,000 and other initial listing standards. Management is monitoring the share price and evaluating options to maintain the listing.
Trinity Biotech plc filed a Form 6-K highlighting two operational milestones. The company’s Premier Hb9210™ HbA1c analyser, with its next‑generation Buffer A Plus column system, achieved IFCC Gold Classification for 2026, making it the only HbA1c system worldwide to receive this top‑tier certification.
The filing also notes full regulatory approval to begin upstream manufacturing of the Uni‑Gold™ HIV rapid test under an offshored and outsourced model. Management describes this as the final major regulatory milestone in its transformation plan and expects the new model to support gross margin expansion, better working capital efficiency, and improved long‑term scalability.
Perceptive Advisors and related funds filed Amendment No. 7 to update their ownership in Trinity Biotech plc. The reporting persons disclose beneficial ownership of 1,463,058,248 Class A Ordinary Shares, representing 9.9% of the class based on 374,206,640 Ordinary Shares outstanding and assuming exercise and conversion of their instruments to the extent permitted by a Beneficial Ownership Cap.
The position is held through Perceptive Credit Holdings II, L.P. and Perceptive Credit Holdings III, L.P. via a mix of warrants, a Convertible Note, and milestone and contingent payment obligations, including 65,000,000 Ordinary Shares issuable upon warrant exercise and 1,165,048,540 Ordinary Shares represented by 58,252,427 ADSs issuable upon conversion of the Convertible Note at a floor price of $1.03. Similar conversion mechanics apply to the milestone and contingent obligations. All of these instruments are contractually restricted so that exercises or conversions cannot raise the reporting group’s beneficial ownership above the 9.9% Beneficial Ownership Cap, and the reporting persons expressly disclaim beneficial ownership above that level.
Trinity Biotech plc is registering up to 55,890,900 American Depositary Shares (ADSs), representing 1,117,818,000 Ordinary Shares, for resale by Perceptive-affiliated selling shareholders. These ADSs are issuable upon conversion of up to $60 million of a convertible note and related payment obligations under conversion agreements with Perceptive funds.
The ADS conversion price is 97% of the volume-weighted average price, subject to a $1.03 floor and a 9.9% beneficial ownership cap. The company will not receive cash from the resale of ADSs and will not receive cash from conversions, but each conversion reduces outstanding debt under the credit agreement and conversion rights. Ordinary Shares outstanding before the sale were 374,206,640, which means full conversion could significantly dilute existing holders, and the company already carries substantial indebtedness, including a term loan due in January 2027.
Trinity Biotech plc has filed to register the resale of up to 55,890,900 American Depositary Shares (ADSs), representing 1,117,818,000 ordinary shares, issuable on conversion of debt owed to Perceptive funds. The ADSs may be issued upon conversion of up to $60,000,000 of a senior convertible note and $12,500,000 of other payment obligations, at a price based on 97% of the ADS volume-weighted average price, subject to a $1.03 floor and a 9.9% beneficial ownership cap.
Trinity will not receive cash from any resale of ADSs by the selling shareholders, but any conversions would reduce outstanding debt under its credit agreement. As of December 31, 2025, the company reported total indebtedness of about $134.58 million, including a term loan of $100.82 million due in January 2027. The company warns that conversions and subsequent sales could cause substantial dilution and pressure on the ADS trading price, and that its high debt load may require additional capital raises or refinancing to continue as a going concern.
Trinity Biotech plc submitted a Form 6-K to provide investors with a press release about its diabetes testing technology. The company announced that it is expanding the global rollout of its high-capacity column system that is used with its FDA-cleared HbA1c testing solution, which helps measure long-term blood sugar control. This expansion follows the company securing the necessary regulatory clearances to offer the system in additional markets. The full details of the announcement are contained in an attached press release, filed as Exhibit 99.1.
Trinity Biotech plc filed a Form 6-K to report that, on November 18, 2025, it issued a press release announcing a major regulatory approval related to manufacturing of its Uni-Gold rapid HIV test. The approval covers offshored and outsourced production of this market-leading diagnostic product.
The company describes this step as part of a broader effort to transform its financial performance, suggesting that the new manufacturing structure is intended to support that strategy. Details of the approval and its expected impact are contained in the press release attached as Exhibit 99.1.
Trinity Biotech plc submitted a Form 6-K to report a corporate update related to its EpiCapture prostate cancer testing technology. The company states that on November 14, 2025 it issued a press release announcing a collaboration to advance epigenetic analysis for its EpiCapture prostate cancer test, and has attached that release as Exhibit 99.1. The filing also notes that this report is incorporated by reference into Trinity Biotech’s existing registration statements on Form S-8.